Thyroid Updates by Professor Steven Boyages

Search This Blog

New guidelines for treating the menopause

on January 26, 2016

Get link
Facebook
X
Pinterest
Email
Other Apps

http://www.endocrinologyadvisor.com/androgen-and-reproductive-disorders/individualized-approach-to-treatment-of-menopause/article/466744/

Get link
Facebook
X
Pinterest
Email
Other Apps

Comments

AnonymousSeptember 29, 2016 at 8:51 PM
Helpful post. Thank you for sharing.
ReplyDelete
Replies

Add comment

How does COVID-19 impact the thyroid?

https://blogs.bcm.edu/2021/01/25/how-does-covid-19-impact-the-thyroid/ Main takeaways are: 1) pre-existing thyroid dysfunction does not lead to an increased COVID-19 infection rate or a worse prognosis during a COVID-19 infection, 2) COVID-19 can cause acute hypothyroidism via the non-thyroidal illness syndrome 3) COVID-19 can cause subacute hyperthyroidism, and 4) COVID-19 can cause overt thyrotoxicosis via direct inflammation of the thyroid. Long-term most acute thyroid dysfunction resolves once the patient has cleared the COVID-19 infection.

Thyroid eye disease: How to treat

Focus on Eyes: Thyroid eye disease can cause a range of problems

Teprotumumab Treats Thyroid Eye Disease Across Age

NEW ORLEANS — Teprotumumab (Tepezza) works equally well in both older and younger patients with thyroid eye disease (TED) and regardless of TED duration, new data suggest. TED is an autoimmune disease characterized by orbital inflammation and expansion of fat and muscles around the eyes, resulting in proptosis, diplopia , pain, redness, and swelling. Many of the patients have Graves disease . In patients aged < 40 years, TED typically lacks restrictive myopathy, involves orbital fat expansion and proptosis with minimal to no periorbital inflammation or diplopia, and has low rates of dysthyroid optic neuropathy (type 1 disease). In contrast, in patients aged 40 years or older, TED often involves restrictive myopathy, along with extraocular muscle (EOM) enlargement and fibrosis, diplopia, and periorbital inflammation, and higher rates of dysthyroid optic neuropathy (type 2 disease). A small study published in 2023 suggested that teprotumumab worked better at reducing E

Powered by Blogger

This information is intended for a general audience and is not a substitute for a doctor's advice.

New guidelines for treating the menopause

Comments

Post a Comment